studies

la/mBC - HR-positive - 2nd line (L2), ribociclib plus endocrine therapy vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsMONALEESA-7, 2018 0.55 [0.44; 0.69] 0.55[0.44; 0.69]MONALEESA-7, 201810%672NAnot evaluable CBRdetailed resultsMONALEESA-7, 2018 1.64 [1.16; 2.33] 1.64[1.16; 2.33]MONALEESA-7, 201810%672NAnot evaluable objective responses (ORR)detailed resultsMONALEESA-7, 2018 1.64 [1.19; 2.26] 1.64[1.19; 2.26]MONALEESA-7, 201810%672NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-18 15:19 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 353,358,359 - treatments: 1403

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons